Neurocrine Biosciences | NBIX - Ordinary Share Capital


Neurocrine Biosciences reported $99.7M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Acadia Pharmaceuticals USD 168.71M 104K Sep/2025
Agios Pharmaceuticals USD 58.28M 241K Sep/2025
ALKERMES USD 165.1M 49K Sep/2025
Alnylam Pharmaceuticals USD 131.79M 130.49M Sep/2025
Amgen USD 538M 300K Sep/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 192.1M 97K Sep/2025
Cytokinetics USD 122.12M 2.52M Sep/2025
Dynavax Technologies USD 117.23M 117.11M Jun/2025
Exelixis USD 268.1M 2.03M Sep/2025
Gilead Sciences USD 1.24B 0 Sep/2025
Halozyme Therapeutics USD 117.52M 98K Sep/2025
Incyte USD 196.13M 2.01M Sep/2025
Ionis Pharmaceuticals USD 161.14M 160.98M Sep/2025
Neurocrine Biosciences USD 99.7M 700K Sep/2025
Pfizer USD 5.69B 1000K Sep/2025
Prothena USD 53.83M 53.29M Sep/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Repligen USD 56.28M 30K Sep/2025
Sarepta Therapeutics USD 104.77M 7.06M Sep/2025
Teva Pharmaceutical Industries USD 1.15B 0 Dec/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vertex Pharmaceuticals USD 254M 2.29M Sep/2025